Free Trial
→ This stock has 30 days of quiet left (From Behind the Markets) (Ad)tc pixel
OTCMKTS:BICX

Biocorrx 3/31/2025 Earnings Report

Biocorrx logo
$0.38 -0.02 (-5.25%)
As of 12:15 PM Eastern
ProfileEarnings HistoryForecast

Biocorrx EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Date
3/31/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Biocorrx Earnings Headlines

BioCorRx Inc.
April 21, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/BICX/financials
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-issuance-u-123000683.html
The SpaceX filing is public. The window is closing.
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.tc pixel
May 26 at 1:00 AM  |  Behind the Markets (Ad)
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without ...
January 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-initiation-clinical-133000445.html
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-announces-appointment-louis-lucido-133000529.html
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-provides-otc-markets-quotation-133000381.html
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile
Earnings Tools